Starling Oncology Inc. Wt cash flow to debt ratio of -23.52% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Starling Oncology Inc. Wt has insufficient data to evaluate this check.

Starling Oncology Inc. Wt has insufficient data to evaluate this check.

Starling Oncology Inc. Wt has insufficient data to evaluate this check.

Starling Oncology Inc. Wt has negative EBITDA, making leverage ratio unreliable

Starling Oncology Inc. Wt's interest coverage ratio is -6.28, which means that the company struggles to meet interest obligations, signaling financial risk.

Starling Oncology Inc. Wt's profit margin has increased (62.40%) in the last year from -16.44% to -6.18%, signaling increasing performance

Starling Oncology Inc. Wt has insufficient data to evaluate this check.

Starling Oncology Inc. Wt's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Starling Oncology Inc. Wt's return on equity of 209.81%, is higher than 15.00%, indicating good performance

Starling Oncology Inc. Wt's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Starling Oncology Inc. Wt has insufficient public price history to evaluate earnings stability.

Starling Oncology Inc. Wt has negative free cash flow, indicating the company is burning cash rather than generating it

Starling Oncology Inc. Wt has negative free cash flow, indicating cash burn

Starling Oncology Inc. Wt's yearly earnings has increased 6.27% since last year from $-64.66M to $-60.61M, signaling increasing performance

Starling Oncology Inc. Wt's yearly revenue has increased 27.79% since last year from $393.41M to $502.73M, signaling increasing performance

ROIC -28.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Starling Oncology Inc. Wt's 3-year revenue CAGR of 25.81% is positive, indicating growing revenue over the past 3 years

Starling Oncology Inc. Wt has insufficient public price history to evaluate revenue consistency.

Starling Oncology Inc. Wt has insufficient public price history to evaluate ROE consistency.

Starling Oncology Inc. Wt has insufficient data to evaluate this check.

Starling Oncology Inc. Wt has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Starling Oncology Inc. Wt is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Starling Oncology Inc. Wt has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Starling Oncology Inc. Wt has insufficient data to evaluate this check.

Starling Oncology Inc. Wt has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Starling Oncology Inc. Wt has negative shareholder equity; price-to-book is not meaningful and the check fails

Starling Oncology Inc. Wt has a price-to-sales ratio of 0.01x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue